Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Two-part, Open-label Dose-escalation and Double-blind, Placebo-controlled Dose-expansion Study With an Open-label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

Next Previous
X
Search
Trial Profile

A Phase 1/2, Two-part, Open-label Dose-escalation and Double-blind, Placebo-controlled Dose-expansion Study With an Open-label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATA 188 Allogeneic (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms EMBOLD
  • Sponsors Atara Biotherapeutics

    • Most Recent Events

    • 22 Feb 2024 Status changed from active, no longer recruiting to discontinued because primary endpoint was not achieved..
    • 08 Nov 2023 The study primary analysis (n= 103) with progressive multiple sclerosis (non-active PPMS and non-active SPMS) published in an Atara Bio media release.
    • 08 Nov 2023 Primary endpoint for Part 2: Percentage of participants with confirmed expanded disability status scale (EDSS) improvement at 12 months has not been met, according to an Atara Bio media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top